Latest News
Review estimates acne risk with JAK inhibitor therapy
Acne has been reported to be an adverse effect of JAK inhibitors, but not much is known about how common acne is overall.
Latest News
FDA approves bimekizumab for moderate to severe plaque psoriasis in adults
With this approval, bimekizumab becomes the only interleukin (IL)-17A and IL-17F inhibitor approved for the treatment of these patients.
Latest News
Study validates use of new psoriatic arthritis prediction tool
To develop the tool, researchers evaluated 635 patients with psoriasis from a prospective longitudinal cohort study evaluating risk factors for...
News
Ustekinumab matches TNF inhibitors for psoriatic arthritis in 3-year, real-world study
A real-world study comparing the interleukin-12/23 inhibitor ustekinumab with tumor necrosis factor inhibitors for psoriatic arthritis found...
News
Psoriatic arthritis has greater impact on women than men
Women with PsA were more likely to have worse disease burden, pain, fatigue, quality of life, and greater disability and work impairment compared...
News
Analysis of PsA guidelines reveals much room for improvement on conflicts of interest
Researchers show that a majority of the authors of the most recent psoriatic arthritis clinical practice guidelines from the American College of...
News
Psoriasis, psoriatic arthritis insurance coverage remains restrictive
A database review showed restrictive coverage of specialty medications for psoriatic disease beyond the label indications.
News
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?
Patients with isolated axial psoriatic arthritis (PsA) were older at diagnosis, more likely to have psoriatic nail lesions, and less likely to...
News
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Patients with immune-mediated inflammatory diseases have weaker vaccine-induced immunity to COVID but are able to build a humoral immune response...
News
Ustekinumab becomes second biologic approved for PsA in kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to...
Conference Coverage
Treat-to-target strategy with tapering proves effective in PsA and axSpA
A trial showed for the first time that disease activity–guided treat-to-target tapering strategies in both psoriatic arthritis and axial...
Conference Coverage
Bimekizumab calms psoriatic arthritis in phase 3 ‘BE’ trials
The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic...
Conference Coverage
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
News
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
News
Trial gives new guidance for choosing initial PsA treatment
Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than...
News
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
News
Methotrexate plus leflunomide proves effective for PsA
The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did...